Peter Louwagie
Person ● Covered in 0 stories + Follow ✴ AI Graph Request update
Peter Louwagie is Senior Vice President of Corporate Development at Genmab, where he is responsible for transactions across discovery, clinical, and commercial stages. He has more than 20 years of experience in inbound and outbound biopharma transactions. Before joining Genmab, he spent more than a decade at Novartis in Basel in roles including Head Transactions Immunology, Global Head BD&L Neuroscience, and Deputy Head Global M&A, and earlier worked in the M&A department of UCB SA in Brussels. He began his career at PwC and is known for leading Genmab’s first M&A deal in 2024, the acquisition of ProfoundBio, followed by the acquisition of Merus NV in 2025.
Updated 8 September 2026
Public sources: informaconnect.com
Why this page exists, and how to correct or remove it
This profile is assembled automatically because Peter Louwagie appears in coverage we index or holds a role listed publicly by their organisation. It uses only public sources — company and organisation pages, news articles, Wikipedia, and public professional listings — and the biography, if any, is written by AI from those sources and cited above.
We hold it to report on the AI industry, under the legitimate interest of journalistic reporting. You can ask us to correct it, restrict it, or take it down, and you can object at any time — no account needed, no reason required.
Claim or correct this profile Request removal How we handle personal data